Drug intelligence / Profile preview

AD282

Development stage: Unknown
Lead developer: Apnimed
Modality: Small Molecules
Administration: Oral

Overview

**AD282** is an investigational small-molecule therapeutic candidate developed by Apnimed for obstructive sleep apnoea. It was evaluated in a completed Australian Phase 1/2 clinical study titled *The effects of AD047 and AD282 on obstructive sleep apnoea*. Publicly accessible sources confirm its association with this study and indication but do not clearly disclose the exact active ingredient, formulation, molecular target, or mechanism of action for AD282 specifically.

Beyond the preview

Go deeper on AD282.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD282.

Explore the full profile